Milsaperidone (VHX-896) vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Result source: NCT00305422
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Quetiapine (Seroquel) |
|---|---|---|
| PANSS total, change | —Not reported | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | —Not reported | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not reported | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not reported | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00305422 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- -33.4 vs -35.9 NCT00882518
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.8 vs -2.1 NCT00882518
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel)
- —Not posted · NCT00305422
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Quetiapine (Seroquel): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Quetiapine (Seroquel) |
|---|---|
| Dropout rate | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 30.4% NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 19.4% NCT00882518 · Phase 3 · registry result, not featured evidence 37.8% NCT00227305 · Phase 3 · registry result, not featured evidence 16.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence — NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 4.6% NCT00882518 · Phase 3 · registry result, not featured evidence 10.5% NCT00227305 · Phase 3 · registry result, not featured evidence 6.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 18.8% NCT00156715 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT00882518 · Phase 3 · registry result, not featured evidence 12.1% NCT00227305 · Phase 3 · registry result, not featured evidence 0% NCT00642369 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a somnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence show 5 more resultspsychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence dry mouth 43.8% sedation 43.8% increased appetite/weight gain 31.3% NCT00156715 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence constipation 25% dizziness 14.3% insomnia 12.8% NCT00882518 · Phase 3 · registry result, not featured evidence somnolence 30.3% increased appetite 20% sedation 18.9% NCT00227305 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Quetiapine (Seroquel)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 12 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05480150 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Available safety results
Quetiapine (Seroquel)
| Dropout rate | 37.8% NCT00227305 · Phase 3 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 10.5% NCT00227305 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 12.1% NCT00227305 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | somnolence 30.3% increased appetite 20% sedation 18.9% NCT00227305 · Phase 3 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Quetiapine (Seroquel)'s landscape